BirchBioMed
BirchBioMed is raising funds through Reg A+ crowdfunding with Dealmaker Securities as the Broker-Dealer. It is a clinical-stage biopharmaceutical company focused on developing treatments for scarring and related skin disorders. BirchBioMed has exclusive and worldwide pharmaceutical licenses from UBC for the scientific technologies FS1/FS2 and AI-001 that hold the potential for medical breakthroughs in the treatment of certain debilitating conditions. Mark S. Miller and Susan Elliott founded BirchBioMed in 2015. The current crowdfunding campaign has a maximum target of $10.35 million. The campaign proceeds will be used to complete Phase 2b and Phase 3 clinical trials for the use of FS2, design and submit to HC for the approval of Phase 1b and Phase 2a trials of AI-001, prepare applications for orphan drug designations, commercialization efforts, and working capital purposes.
BirchBioMed is raising funds through Reg A+ crowdfunding with Dealmaker Securities as the Broker-Dealer. It is a clinical-stage biopharmaceutical company focused on developing treatments for scarring and related skin disorders. BirchBioMed has exclusive and worldwide pharmaceutical licenses from UBC for the scientific technologies FS1/FS2 and AI-001 that hold the potential for medical breakthroughs in the treatment of certain debilitating conditions. Mark S. Miller and Susan Elliott founded BirchBioMed in 2015. The current crowdfunding campaign has a maximum target of $10.35 million. The campaign proceeds will be used to complete Phase 2b and Phase 3 clinical trials for the use of FS2, design and submit to HC for the approval of Phase 1b and Phase 2a trials of AI-001, prepare applications for orphan drug designations, commercialization efforts, and working capital purposes.
Stay in the Loop
Get updates from BirchBioMed
Get exclusive updates from BirchBioMed
Be the first to know about company milestones, news, and opportunities.
🔒 No spam. Just real progress.
Company Stats
Key metrics about BirchBioMed
Are you the owner of BirchBioMed?
Claim your company profile to respond to reviews, update your information, and connect with investors.
Claim This Company